AMT

aminomethyltransferase, the group of Methyltransferase families

Basic information

Region (hg38): 3:49416778-49422685

Links

ENSG00000145020NCBI:275OMIM:238310HGNC:473Uniprot:P48728AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • glycine encephalopathy (Definitive), mode of inheritance: AR
  • neonatal glycine encephalopathy (Supportive), mode of inheritance: AR
  • infantile glycine encephalopathy (Supportive), mode of inheritance: AR
  • atypical glycine encephalopathy (Supportive), mode of inheritance: Unknown
  • glycine encephalopathy (Strong), mode of inheritance: AR
  • glycine encephalopathy (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Glycine encephalopathy 2ARBiochemical; PharmacogenomicThere is no current effective treatment for severe disease; however, children with mutations associated with residual GCS enzyme activity treated aggressively early with sodium benzoate and N-methyl D-aspartate receptor site antagonists may have improved outcomes; Valproate should be avoidedBiochemical; Neurologic; Ophthalmologic11139253; 12948742; 16151895; 16450403; 20301531; 19299230; 21470805; 28462797

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the AMT gene.

  • Glycine encephalopathy (49 variants)
  • Glycine encephalopathy 2 (6 variants)
  • Glycine encephalopathy 1 (4 variants)
  • not provided (3 variants)
  • Inborn genetic diseases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the AMT gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
191
clinvar
1
clinvar
193
missense
4
clinvar
28
clinvar
153
clinvar
4
clinvar
189
nonsense
11
clinvar
6
clinvar
1
clinvar
18
start loss
2
clinvar
2
clinvar
4
frameshift
27
clinvar
27
clinvar
2
clinvar
56
inframe indel
1
clinvar
1
clinvar
7
clinvar
9
splice donor/acceptor (+/-2bp)
5
clinvar
15
clinvar
2
clinvar
22
splice region
2
8
34
44
non coding
15
clinvar
95
clinvar
9
clinvar
119
Total 50 79 181 290 10

Highest pathogenic variant AF is 0.0000394

Variants in AMT

This is a list of pathogenic ClinVar variants found in the AMT region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
3-49416844-G-A Glycine encephalopathy Benign (Jan 13, 2018)346021
3-49416862-G-C Glycine encephalopathy Uncertain significance (Jan 12, 2018)346022
3-49416919-T-C Glycine encephalopathy Uncertain significance (Jan 13, 2018)899656
3-49416924-G-A Glycine encephalopathy Uncertain significance (Jan 13, 2018)899657
3-49416995-G-A Glycine encephalopathy Uncertain significance (Jan 12, 2018)346023
3-49417116-C-G Glycine encephalopathy Uncertain significance (Jan 13, 2018)346024
3-49417124-G-A Glycine encephalopathy Likely benign (Jan 12, 2018)900802
3-49417133-A-G Glycine encephalopathy Uncertain significance (Jan 13, 2018)346025
3-49417377-C-G Glycine encephalopathy Uncertain significance (Jan 12, 2018)346026
3-49417410-C-A Glycine encephalopathy Likely benign (Jan 12, 2018)346027
3-49417454-C-A Glycine encephalopathy • Inborn genetic diseases Uncertain significance (Aug 10, 2022)553667
3-49417542-AC-A Glycine encephalopathy Uncertain significance (Mar 10, 2021)554761
3-49417545-TGAG-T Glycine encephalopathy Uncertain significance (Aug 04, 2023)1442556
3-49417546-G-C Glycine encephalopathy Likely benign (Jan 18, 2023)1567896
3-49417548-G-A Glycine encephalopathy Uncertain significance (Sep 27, 2022)1931073
3-49417549-G-A Glycine encephalopathy Likely benign (May 04, 2021)1556537
3-49417550-G-T Glycine encephalopathy Uncertain significance (Aug 09, 2022)1052844
3-49417550-GTAT-ATA Glycine encephalopathy Uncertain significance (Aug 02, 2017)553002
3-49417553-T-C Glycine encephalopathy Uncertain significance (Jan 15, 2018)900803
3-49417553-T-G Glycine encephalopathy Uncertain significance (Aug 22, 2022)1988801
3-49417554-A-G Glycine encephalopathy Uncertain significance (Aug 13, 2021)2173098
3-49417555-G-A Glycine encephalopathy Likely benign (Dec 12, 2023)1109882
3-49417561-T-G Glycine encephalopathy Likely benign (Aug 23, 2021)1642987
3-49417562-G-T Glycine encephalopathy Uncertain significance (Jun 14, 2016)346028
3-49417565-G-A Glycine encephalopathy Uncertain significance (Jul 16, 2022)2076615

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
AMTprotein_codingprotein_codingENST00000273588 95976
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.002720.9851257120361257480.000143
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.1012442401.020.00001492610
Missense in Polyphen8093.4250.85631045
Synonymous-0.47210195.11.060.00000570861
Loss of Function2.19716.70.4208.27e-7193

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0004520.000447
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.00009240.0000924
European (Non-Finnish)0.00009820.0000967
Middle Eastern0.000.00
South Asian0.0002940.000294
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: The glycine cleavage system catalyzes the degradation of glycine. {ECO:0000269|PubMed:16051266}.;
Disease
DISEASE: Non-ketotic hyperglycinemia (NKH) [MIM:605899]: Autosomal recessive disease characterized by accumulation of a large amount of glycine in body fluid and by severe neurological symptoms. {ECO:0000269|PubMed:10873393, ECO:0000269|PubMed:11286506, ECO:0000269|PubMed:16051266, ECO:0000269|PubMed:26371980, ECO:0000269|PubMed:28244183, ECO:0000269|PubMed:8005589, ECO:0000269|PubMed:9600239, ECO:0000269|PubMed:9621520}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
One carbon pool by folate - Homo sapiens (human);Glycine, serine and threonine metabolism - Homo sapiens (human);Glyoxylate and dicarboxylate metabolism - Homo sapiens (human);3-Phosphoglycerate dehydrogenase deficiency;Non Ketotic Hyperglycinemia;Ammonia Recycling;Glycine and Serine Metabolism;Dimethylglycine Dehydrogenase Deficiency;Hyperglycinemia, non-ketotic;Dimethylglycine Dehydrogenase Deficiency;Sarcosinemia;Dihydropyrimidine Dehydrogenase Deficiency (DHPD);One Carbon Metabolism;Trans-sulfuration and one carbon metabolism;Folate metabolism;Glycine degradation;Metabolism of amino acids and derivatives;Metabolism;Vitamin B9 (folate) metabolism;Glyoxylate metabolism and glycine degradation;Glycine, serine, alanine and threonine metabolism;glycine cleavage (Consensus)

Recessive Scores

pRec
0.277

Intolerance Scores

loftool
0.0987
rvis_EVS
-0.38
rvis_percentile_EVS
28.01

Haploinsufficiency Scores

pHI
0.391
hipred
N
hipred_score
0.473
ghis
0.547

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.0200

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Amt
Phenotype
nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);

Gene ontology

Biological process
glycine catabolic process;glycine decarboxylation via glycine cleavage system;methylation
Cellular component
nucleoplasm;mitochondrion;mitochondrial matrix
Molecular function
aminomethyltransferase activity;transaminase activity